Skip to main content
Premium Trial:

Request an Annual Quote

Protein Analysis Firm Nicoya Raises C$20M in Extended Series A Financing Round

NEW YORK – Canadian protein analysis company Nicoya Lifesciences said on Thursday that it has raised C$20 million (US$15.7 million) in an extended Series A financing, bringing its total funding to date to C$35 million.

The extension was led by Whitecap Venture Partners, with participation from Agilent Technologies, Export Development Canada, BDC Capital, MaRS IAF, and Garage Capital. Whitecap also led the earlier $10 million Series A financing in 2020, which enabled Nicoya to grow to over 100 employees and launch an early adopter program.

The new funding will help the Kitchener, Ontario-based company continue to develop and commercialize its Alto surface plasmon resonance (SPR)-based platform and expand into international markets. Alto integrates SPR with digital microfluidics to perform multiplexed and label-free protein characterization.

The company said its products are currently used by over 500 researchers and that it intends to continue expanding in the academic, government, biotechnology, and pharmaceutical sectors.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.